CO2022009437A2 - Composiciones farmacéuticas tópicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo - Google Patents
Composiciones farmacéuticas tópicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitriloInfo
- Publication number
- CO2022009437A2 CO2022009437A2 CONC2022/0009437A CO2022009437A CO2022009437A2 CO 2022009437 A2 CO2022009437 A2 CO 2022009437A2 CO 2022009437 A CO2022009437 A CO 2022009437A CO 2022009437 A2 CO2022009437 A2 CO 2022009437A2
- Authority
- CO
- Colombia
- Prior art keywords
- dimethylpent
- pyrazolo
- pyrimidin
- piperidine
- fluoro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente memoria se proporcionan composiciones farmacéuticas tópicas, por ejemplo, para su aplicación en la piel de un sujeto, que comprenden (R)-2-(3-(4-amino-3-(2-fluoro-4-fenoxifenil)-1H-pirazolo[3,4-d]pirimidin-1-il)piperidina-1-carbonil)-4,4-dimetilpent-2-enonitrilo (Compuesto (I)), métodos de preparación de las mismas y métodos de uso de las mismas, por ejemplo, para el tratamiento de diversos trastornos dermatológicos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062958616P | 2020-01-08 | 2020-01-08 | |
US202063003536P | 2020-04-01 | 2020-04-01 | |
PCT/US2021/012507 WO2021142124A1 (en) | 2020-01-08 | 2021-01-07 | Topical pharmaceutical compositions comprising 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4,4-dimethylpent-2-enenitrile |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022009437A2 true CO2022009437A2 (es) | 2022-12-09 |
Family
ID=74626093
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0009437A CO2022009437A2 (es) | 2020-01-08 | 2022-07-05 | Composiciones farmacéuticas tópicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo |
Country Status (13)
Country | Link |
---|---|
US (2) | US11583533B2 (es) |
EP (1) | EP4087537A1 (es) |
JP (1) | JP2023510244A (es) |
KR (1) | KR20220124753A (es) |
CN (1) | CN115605181A (es) |
AU (1) | AU2021205248A1 (es) |
BR (1) | BR112022012974A2 (es) |
CA (1) | CA3163850A1 (es) |
CO (1) | CO2022009437A2 (es) |
IL (1) | IL294537A (es) |
MX (1) | MX2022008428A (es) |
TW (1) | TW202142237A (es) |
WO (1) | WO2021142124A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202342048A (zh) * | 2022-02-28 | 2023-11-01 | 瑞士商諾華公司 | 使用lou064治療化膿性汗腺炎之方法 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7547443B2 (en) * | 2003-09-11 | 2009-06-16 | Kimberly-Clark Worldwide, Inc. | Skin care topical ointment |
US20090186943A1 (en) * | 2006-02-15 | 2009-07-23 | Masahiro Ikeda | Antiseptic Ointment |
PT2710005T (pt) | 2011-05-17 | 2016-11-16 | Principia Biopharma Inc | Inibidores de tirosina-quinase |
EP2710007B1 (en) | 2011-05-17 | 2019-12-11 | The Regents of The University of California | Kinase inhibitors |
DK2861599T3 (da) | 2012-06-18 | 2020-03-02 | Principia Biopharma Inc | Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme |
US9572811B2 (en) | 2012-08-03 | 2017-02-21 | Principia Biopharma Inc. | Treatment of dry eye |
ES2731833T3 (es) | 2012-09-10 | 2019-11-19 | Principia Biopharma Inc | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
JP6504548B2 (ja) * | 2014-02-21 | 2019-04-24 | プリンシピア バイオファーマ インコーポレイテッド | Btk阻害剤の塩および固体形態 |
US10485797B2 (en) | 2014-12-18 | 2019-11-26 | Principia Biopharma Inc. | Treatment of pemphigus |
US20170224688A1 (en) * | 2016-02-04 | 2017-08-10 | Acerta Pharma B.V. | Methods of Using BTK Inhibitors to Treat Dermatoses |
BR112018077503A2 (pt) * | 2016-06-29 | 2019-04-09 | Principia Biopharma Inc. | formulações de liberação modificada de 2-[3-[4-amino-3-(2-fluoro-4- fenoxi-fenil)pirazolo [3,4-d]pirimidin-1-il]piperidino-1- carbonil]-4-metil-4-[4-(oxetan-3-il)piperazin-1-il] pent-2-enenitrila |
WO2022081512A1 (en) | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
-
2021
- 2021-01-07 US US17/143,384 patent/US11583533B2/en active Active
- 2021-01-07 TW TW110100563A patent/TW202142237A/zh unknown
- 2021-01-07 IL IL294537A patent/IL294537A/en unknown
- 2021-01-07 WO PCT/US2021/012507 patent/WO2021142124A1/en active Application Filing
- 2021-01-07 JP JP2022541615A patent/JP2023510244A/ja active Pending
- 2021-01-07 CA CA3163850A patent/CA3163850A1/en active Pending
- 2021-01-07 AU AU2021205248A patent/AU2021205248A1/en active Pending
- 2021-01-07 CN CN202180018442.7A patent/CN115605181A/zh active Pending
- 2021-01-07 BR BR112022012974A patent/BR112022012974A2/pt unknown
- 2021-01-07 KR KR1020227026981A patent/KR20220124753A/ko active Search and Examination
- 2021-01-07 MX MX2022008428A patent/MX2022008428A/es unknown
- 2021-01-07 EP EP21705667.0A patent/EP4087537A1/en active Pending
-
2022
- 2022-07-05 CO CONC2022/0009437A patent/CO2022009437A2/es unknown
-
2023
- 2023-01-12 US US18/153,528 patent/US20230277542A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2022008428A (es) | 2022-08-08 |
WO2021142124A1 (en) | 2021-07-15 |
KR20220124753A (ko) | 2022-09-14 |
CN115605181A (zh) | 2023-01-13 |
EP4087537A1 (en) | 2022-11-16 |
JP2023510244A (ja) | 2023-03-13 |
IL294537A (en) | 2022-09-01 |
US11583533B2 (en) | 2023-02-21 |
US20210205313A1 (en) | 2021-07-08 |
TW202142237A (zh) | 2021-11-16 |
US20230277542A1 (en) | 2023-09-07 |
CA3163850A1 (en) | 2021-07-15 |
BR112022012974A2 (pt) | 2022-09-13 |
AU2021205248A1 (en) | 2022-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60325379D1 (de) | Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen | |
CL2011003346A1 (es) | Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente. | |
NI200900091A (es) | Sales y formas de cristal del 2-metil-2-[4-(3-metil-2-oxo-8-quinolin-3-il-2,3-dihidro-imidazo-[4,5-c]-quinolin-1-il)- fenil]-propionitrilo | |
GT200500359A (es) | Compuestos organicos | |
PA8748101A1 (es) | Benzoxazoles y oxazolopiridinas que son utiles como inhibidores de las cinasas janus | |
PA8621901A1 (es) | Derivados de sulfonamida para el tratamiento de enfermedades | |
GT200600089A (es) | Compuestos organicos | |
ECSP055524A (es) | Derivados de indolin-fenilsufonamida | |
AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
GT200600316A (es) | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
ECSP11011113A (es) | Piridiloxi-indoles inhibidores del vegf-r2 y uso de los mismos para el tratamiento de enfermedades | |
UY30681A1 (es) | Compuestos de piridinamida que contienen carboxi, sales farmacéuticamente aceptables, procedimientos para la preparacion de los mismos, composiciones que los contienen y sus usos. | |
CL2007001388A1 (es) | Co-cristal de maleato de 2{etil[3-({4-[(5-{2-[(3-fluorfenil)amino]-2-oxoetil}-1h-pirazol-3-il)amino]quinazolin-7-il}oxi)propil]amino}fosfato dihidrogeno de etilo (azd1152), inhibidor de aurora quinasa; metodo de preparacion; composicion farmaceutica; y uso para el tratamiento de enfermedades hiperproliferativas como el cancer. | |
AR064149A1 (es) | Sal fumarato de (alfa s , beta r)-6 bromo- alfa-[ 2(dimetilamino ) etil)-2- metoxi - alfa-1-naftalenil- beta- fenil-3- quinolinaetanol | |
UY37149A (es) | 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas | |
HN2008001666A (es) | Derivados acidos de cicloalquilamino | |
PA8627001A1 (es) | Compuestos para el tratamiento de enfermedades | |
SV2006002135A (es) | Nucleosidos de 3-beta-d-ribofuranosiltiazolo [4,5-d] pirimidina y usos de los mismos | |
BRPI0519070A2 (pt) | composiÇço de fator de crescimento de queratinàcito liofilizada, mÉtodos para preparar um fator de crescimento de queratinàcito liofilizado, e para tratar uma doenÇa, e, kit para preparar uma composiÇço farmacÊutica aquosa | |
CL2011003144A1 (es) | Forma cristalina e3 de bisulfato de atazanavir; composicion farmaceutica que la comprende; util para el tratamiento de enfermedades originadas por retrovirus (divisional de la solicitud 1057-05). | |
CO2022009437A2 (es) | Composiciones farmacéuticas tópicas que comprenden 2-[3-[4-amino-3-(2-fluoro-4-fenoxi-fenil)-1h-pirazolo[3,4-d]pirimidin-1-il]piperidina-1-carbonil]-4,4-dimetilpent-2-enonitrilo | |
CL2023003518A1 (es) | Nuevas sales y formas cristalinas de sales de n,n-dimetiltriptamina | |
AR117614A1 (es) | Forma de dosificación farmacéutica administrable por vía oral con liberación modificada | |
PA8661701A1 (es) | Tiazolidinonas, su preparacion y su uso como medicamento | |
PA8514901A1 (es) | Metabolitos agonistas/antagonistas de estrogeno |